BioCentury | Feb 23, 2015
Company News

IntegraGen S.A, Esperite deal

IntegraGen granted Esperite's Genoma S.A. (Geneva, Switzerland) subsidiary rights to commercialize ARISk buccal swab test, which diagnoses the risk of autism spectrum disorder in children less than 48 months of age. Genoma will market the...
BioCentury | Aug 11, 2014
Company News

AutoGenomics, Genomas deal

...AutoGenomics and Genomas partnered to develop genetic tests and DNA-guided diagnostic systems to optimally select statins...
...high-dose statin therapy. The companies will use AutoGenomics’ Infiniti molecular diagnostics platform in combination with Genomas’...
...therapy. AutoGenomics and Genomas could not be reached for details. AutoGenomics Inc. , Vista, Calif. Genomas Inc....
BioCentury | Jul 14, 2014
Company News

Illumina Inc, Biomnis, Genoma, Center for Human Genetics and Laboratory Medicine deal

Illumina entered into separate agreements with Biomnis, Genoma and the Center for Human Genetics and Laboratory Medicine to use Illumina’s HiSeq 2500 sequencing system and consumables to develop and perform non-invasive prenatal testing. Biomnis plans...
BioCentury | Jul 13, 2009
Clinical News

Genomas preclinical data

Genomas Inc. , Hartford, Conn. Product: SINM PhyzioType System Indication: Predict risk of statin-induced neuromyopathy Based on blood samples from 442 subjects on statin treatment, the company characterized 384 SNPs from 222 cardiometabolic and neuroendocrine genes...
BioCentury | May 25, 2009
Regulation

PDX coverage gap

...Ruaño, president of Genomas Inc. and director of genetics research at Hartford Hospital , told BioCentury Genomas...
...Md. Cleveland Clinic Genomic Medicine Institute , Cleveland, Ohio Foley Hoag LLP , Boston, Mass. Genomas Inc....
BioCentury | Jul 17, 2008
Cover Story

Merck's Rosetta stone

...getting," said Russ Dietrich, XDx's director of molecular immunology. Gualberto Ruao, president and CEO of Genomas Inc....
...many individuals," he said. "Looking at gene expression is a step in the right direction." Genomas...
...Seattle, Wash. e-mail: eric_schadt@merck.com COMPANIES and INSTITUTIONS MENTIONED deCODE genetics Inc. (NASDAQ:DCGN), Reykjavik, Iceland Genomas Inc....
BioCentury | May 22, 2006
Strategy

Content meets conduit

...content-related deal was in 2004, when ILMN partnered to identify markers of metabolic syndrome with Genomas Inc....
BioCentury | Oct 21, 2004
Politics & Policy

Personalized Medicine Coalition launched

...Affymetrix (AFFY); Amgen (AMGN); AstraZeneca (LSE:AZN; AZN); the Biotechnology Industry Organization (BIO); Genentech (DNA); Genomas...
Items per page:
1 - 8 of 8
BioCentury | Feb 23, 2015
Company News

IntegraGen S.A, Esperite deal

IntegraGen granted Esperite's Genoma S.A. (Geneva, Switzerland) subsidiary rights to commercialize ARISk buccal swab test, which diagnoses the risk of autism spectrum disorder in children less than 48 months of age. Genoma will market the...
BioCentury | Aug 11, 2014
Company News

AutoGenomics, Genomas deal

...AutoGenomics and Genomas partnered to develop genetic tests and DNA-guided diagnostic systems to optimally select statins...
...high-dose statin therapy. The companies will use AutoGenomics’ Infiniti molecular diagnostics platform in combination with Genomas’...
...therapy. AutoGenomics and Genomas could not be reached for details. AutoGenomics Inc. , Vista, Calif. Genomas Inc....
BioCentury | Jul 14, 2014
Company News

Illumina Inc, Biomnis, Genoma, Center for Human Genetics and Laboratory Medicine deal

Illumina entered into separate agreements with Biomnis, Genoma and the Center for Human Genetics and Laboratory Medicine to use Illumina’s HiSeq 2500 sequencing system and consumables to develop and perform non-invasive prenatal testing. Biomnis plans...
BioCentury | Jul 13, 2009
Clinical News

Genomas preclinical data

Genomas Inc. , Hartford, Conn. Product: SINM PhyzioType System Indication: Predict risk of statin-induced neuromyopathy Based on blood samples from 442 subjects on statin treatment, the company characterized 384 SNPs from 222 cardiometabolic and neuroendocrine genes...
BioCentury | May 25, 2009
Regulation

PDX coverage gap

...Ruaño, president of Genomas Inc. and director of genetics research at Hartford Hospital , told BioCentury Genomas...
...Md. Cleveland Clinic Genomic Medicine Institute , Cleveland, Ohio Foley Hoag LLP , Boston, Mass. Genomas Inc....
BioCentury | Jul 17, 2008
Cover Story

Merck's Rosetta stone

...getting," said Russ Dietrich, XDx's director of molecular immunology. Gualberto Ruao, president and CEO of Genomas Inc....
...many individuals," he said. "Looking at gene expression is a step in the right direction." Genomas...
...Seattle, Wash. e-mail: eric_schadt@merck.com COMPANIES and INSTITUTIONS MENTIONED deCODE genetics Inc. (NASDAQ:DCGN), Reykjavik, Iceland Genomas Inc....
BioCentury | May 22, 2006
Strategy

Content meets conduit

...content-related deal was in 2004, when ILMN partnered to identify markers of metabolic syndrome with Genomas Inc....
BioCentury | Oct 21, 2004
Politics & Policy

Personalized Medicine Coalition launched

...Affymetrix (AFFY); Amgen (AMGN); AstraZeneca (LSE:AZN; AZN); the Biotechnology Industry Organization (BIO); Genentech (DNA); Genomas...
Items per page:
1 - 8 of 8